Tags

Type your tag names separated by a space and hit enter

Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients.
Diabetes Care. 1995 Nov; 18(11):1487-90.DC

Abstract

OBJECTIVE

To measure the effects of cyclosporin A (CyA) with no insulin therapy on glucose tolerance and beta-cell function in the preclinical phase of insulin-dependent diabetes mellitus (IDDM).

RESEARCH DESIGN AND METHODS

beta-cell responses to the intravenous glucose tolerance test (IVGTT), hyperglycemic clamp, intravenous arginine, and intravenous glucagon were evaluated before and after a 6-month course of CyA in seven patients (mean age 19.6 years) with asymptomatic IDDM.

RESULTS

Initial insulin secretory responses were severely decreased when the patients were compared with eight healthy control subjects: IVGTT (1 + 3 min): 106 +/- 16 vs. 884 +/- 190 pmol/l (P < 0.001); hyperglycemic clamp: 102 +/- 16 vs. 310 +/- 42 pmol/l (P < 0.001); intravenous arginine: 346 +/- 72 vs. 1104 +/- 168 pmol/l (P < 0.01); and intravenous glucagon: 170 +/- 37 vs. 247 +/- 35 pmol/l (NS). The beta-cell responses remained markedly abnormal after 6 months of CyA, although the response to intravenous glucose and oral glucose tolerance tests improved in three subjects. All the patients became insulin-dependent after 5-36 months.

CONCLUSIONS

CyA alone is not a suitable treatment for asymptomatic IDDM. Earlier identification of subjects with substantial beta-cell secretory capacity and newer nontoxic intervention strategies are required for the prevention of IDDM.

Authors+Show Affiliations

Department of Pediatric Diabetology and Inserm U 30, Hôpital Necker-Enfants Malades, Paris, France.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

8722075

Citation

Rakotoambinina, B, et al. "Cyclosporin a Does Not Delay Insulin Dependency in Asymptomatic IDDM Patients." Diabetes Care, vol. 18, no. 11, 1995, pp. 1487-90.
Rakotoambinina B, Timsit J, Deschamps I, et al. Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care. 1995;18(11):1487-90.
Rakotoambinina, B., Timsit, J., Deschamps, I., Laborde, K., Jos, J., Boitard, C., Assan, R., & Robert, J. J. (1995). Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. Diabetes Care, 18(11), 1487-90.
Rakotoambinina B, et al. Cyclosporin a Does Not Delay Insulin Dependency in Asymptomatic IDDM Patients. Diabetes Care. 1995;18(11):1487-90. PubMed PMID: 8722075.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Cyclosporin A does not delay insulin dependency in asymptomatic IDDM patients. AU - Rakotoambinina,B, AU - Timsit,J, AU - Deschamps,I, AU - Laborde,K, AU - Jos,J, AU - Boitard,C, AU - Assan,R, AU - Robert,J J, PY - 1995/11/1/pubmed PY - 1995/11/1/medline PY - 1995/11/1/entrez SP - 1487 EP - 90 JF - Diabetes care JO - Diabetes Care VL - 18 IS - 11 N2 - OBJECTIVE: To measure the effects of cyclosporin A (CyA) with no insulin therapy on glucose tolerance and beta-cell function in the preclinical phase of insulin-dependent diabetes mellitus (IDDM). RESEARCH DESIGN AND METHODS: beta-cell responses to the intravenous glucose tolerance test (IVGTT), hyperglycemic clamp, intravenous arginine, and intravenous glucagon were evaluated before and after a 6-month course of CyA in seven patients (mean age 19.6 years) with asymptomatic IDDM. RESULTS: Initial insulin secretory responses were severely decreased when the patients were compared with eight healthy control subjects: IVGTT (1 + 3 min): 106 +/- 16 vs. 884 +/- 190 pmol/l (P < 0.001); hyperglycemic clamp: 102 +/- 16 vs. 310 +/- 42 pmol/l (P < 0.001); intravenous arginine: 346 +/- 72 vs. 1104 +/- 168 pmol/l (P < 0.01); and intravenous glucagon: 170 +/- 37 vs. 247 +/- 35 pmol/l (NS). The beta-cell responses remained markedly abnormal after 6 months of CyA, although the response to intravenous glucose and oral glucose tolerance tests improved in three subjects. All the patients became insulin-dependent after 5-36 months. CONCLUSIONS: CyA alone is not a suitable treatment for asymptomatic IDDM. Earlier identification of subjects with substantial beta-cell secretory capacity and newer nontoxic intervention strategies are required for the prevention of IDDM. SN - 0149-5992 UR - https://www.unboundmedicine.com/medline/citation/8722075/Cyclosporin_A_does_not_delay_insulin_dependency_in_asymptomatic_IDDM_patients_ L2 - http://ovidsp.ovid.com/ovidweb.cgi?T=JS&amp;PAGE=linkout&amp;SEARCH=8722075.ui DB - PRIME DP - Unbound Medicine ER -